| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-065 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 鉴于公司于 2025 年 7 月 10 日在中国证券登记结算有限责任公司深圳分公 司办理完成 3,999,287 股回购股份的注销事宜，公司总股本由 564,265,375 股变更 为 560,266,088 股。具体内容详见公司于 2025 年 7 月 11 日在中国证监会指定的 创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露的《关于部分回购 股份注销完成暨股份变动的公告》（公告编号：2025-063）。 公司于近日完成了上述注册资本及《公司章程》的工商变更登记及备案等相 关手续，并取得了长沙市市场监督管理局换发的新《营业执照》，现将相关情况 公告如下： 一、新《营业执照》基本信息 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）分别于 2025 年 ...

Core Points - The company has completed the adjustment of the conversion price for its convertible bonds following the repurchase and cancellation of shares [1][7][8] Group 1: Convertible Bond Issuance - The company issued 5 million convertible bonds with a total value of 500 million RMB, with an initial conversion price set at 35.35 RMB per share [1] - The bonds were approved by the China Securities Regulatory Commission and began trading on January 12, 2021 [1] Group 2: Conversion Price Adjustment Mechanism - The conversion price is subject to adjustments based on various corporate actions such as stock dividends, capital increases, and cash dividends, following specific formulas [2][3] - The adjustment formulas account for factors like stock dividend rates, new share issuance rates, and cash dividend amounts [2] Group 3: Historical Adjustments - The conversion price has undergone several adjustments due to corporate actions, including a reduction from 35.35 RMB to 35.15 RMB on June 11, 2021, following a cash dividend distribution [3][5] - Subsequent adjustments included changes to 34.98 RMB on May 25, 2022, and 34.81 RMB on May 26, 2023, due to similar corporate actions [5][6] Group 4: Recent Adjustments - Following the repurchase and cancellation of 3,999,287 shares, the total share capital decreased from 564,265,375 to 560,266,088 shares [7] - The conversion price was adjusted from 34.39 RMB to 34.46 RMB, effective from July 14, 2025, based on the repurchase price and the number of shares canceled [7][8]

Core Viewpoint - Sanofi Biosensor Co., Ltd. announced an adjustment in the conversion price of its convertible bonds, increasing it from 34.39 CNY/share to 34.46 CNY/share, effective from July 14, 2025 [1][4]. Summary by Relevant Sections Conversion Price Adjustment Basis - The adjustment is based on the approval from the China Securities Regulatory Commission for the issuance of convertible bonds, which were initially priced at 35.35 CNY/share [2]. - The conversion price must be adjusted in response to events such as stock dividends, capital increases, or share buybacks that affect the company's equity structure [2]. Historical Adjustment of Conversion Price - The conversion price has undergone several adjustments since its initial issuance: - June 11, 2021: Adjusted from 35.35 CNY/share to 35.15 CNY/share due to a cash dividend of 2 CNY per 10 shares [3]. - August 20, 2021: Adjusted to 35.18 CNY/share following the buyback of restricted stock [3]. - May 25, 2022: Adjusted to 34.98 CNY/share due to another cash dividend [3]. - September 28, 2022: Adjusted to 35.01 CNY/share after further stock buybacks [3]. - May 26, 2023: Adjusted to 34.81 CNY/share due to a cash dividend [3]. - June 17, 2024: Adjusted to 34.61 CNY/share following another cash dividend [3]. - June 13, 2025: Adjusted to 34.39 CNY/share due to a cash dividend of 2.20 CNY per 10 shares [3]. Details of the Current Adjustment - The company held board and shareholder meetings to approve the cancellation of 3,999,287 shares, which is 0.71% of the total shares before cancellation [4]. - Following the cancellation, the total share capital decreased from 564,265,375 shares to 560,266,088 shares, leading to the new conversion price of 34.46 CNY/share [4].

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-064 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于回购股份注销完成调整可转换公司债券转股价格 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 一、关于可转换公司债券转股价格调整的相关规定 经中国证券监督管理委员会（以下简称"中国证监会"）《关于三诺生物股 份有限公司公开发行可转换公司债券的批复》（证监许可〔2020〕2951号）核准， 三诺生物传感股份有限公司（以下简称"公司"）于2020年12月21日向不特定对 象共发行500.00万张可转换公司债券，每张面值人民币100元，发行总额50,000.00 万元，本次可转换公司债券已于2021年1月12日起在深交所挂牌交易。债券简称 "三诺转债"，债券代码"123090"。三诺转债初始转股价格为35.35元/股。 根据《三诺生物传感股份有限公司创业板向不特定对象发行可转换公司债券 募集说明书》（以下简称"《募集说明书》"）相关条 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-063 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于部分回购股份注销完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、三诺生物传感股份有限公司（以下简称"公司"）本次注销的回购股份数 量为 3,999,287 股，占注销前公司总股本的比例为 0.71%，回购注销金额为人民 币 96,327,030.98 元。本次注销完成后，公司总股本由 564,265,375 变更为 560,266,088 股。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次回购 股份注销事宜已于 2025 年 7 月 10 日办理完成。 3、本次回购股份注销完成后，公司可转债转股价格将由 34.39 元/股调整为 34.46 元/股，调整后的转股价格自 2025 年 7 月 14 日起生效。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of Sanofi Biologicals in the medical device industry, particularly in blood glucose monitoring systems [1][2] - As of July 9, Sanofi Biologicals closed at 22.25 yuan, with a rolling PE ratio of 39.55 times and a total market capitalization of 12.555 billion yuan [1] - The average PE ratio for the medical device industry is 51.36 times, with a median of 37.22 times, placing Sanofi Biologicals at the 81st position in the industry ranking [1][2] Group 2 - As of the first quarter of 2025, 23 institutions hold shares in Sanofi Biologicals, including 21 funds, with a total holding of 97.2415 million shares valued at 2.313 billion yuan [1] - The main business of Sanofi Biologicals is the production and sale of blood glucose monitoring systems, along with related products such as diabetes nutrition and care products, blood lipid testing systems, and blood pressure monitors [1] - In the latest financial report for the first quarter of 2025, the company achieved an operating income of 1.042 billion yuan, a year-on-year increase of 2.76%, and a net profit of 72.1151 million yuan, a year-on-year decrease of 10.90%, with a gross profit margin of 48.69% [1]

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector, particularly in innovative drugs, predicting a reversal trend in 2025 [4] Core Viewpoints - The innovative drug sector is experiencing strong performance driven by multiple factors, including the completion of quarterly portfolio adjustments, increased policy support from the National Healthcare Security Administration (NHSA) and the National Health Commission, and significant collaborations in the industry [1][11] - The NHSA and the National Health Commission have jointly released measures to support the high-quality development of innovative drugs, which will accelerate the commercialization of domestic innovative products and create a positive cycle of profitability and strong R&D investment [20][21] - The report highlights the potential of dual/multi-target antibodies in cancer treatment and innovative drugs addressing unmet clinical needs in chronic diseases as key investment opportunities [1][4] Summary by Sections Innovative Drugs - The innovative drug sector remains the main investment line, with a focus on dual/multi-target antibodies for various cancers and chronic diseases [1][11] - AstraZeneca is in talks for a collaboration worth up to $15 billion for the AK112 drug, which has catalyzed strong performance in related stocks [1] Pharmaceutical Sector - The NHSA's new measures will direct more healthcare resources towards innovative drugs, enhancing their commercialization and profitability [20][21] - The report notes that since 2018, 149 innovative drugs have been included in the healthcare insurance directory, significantly increasing the proportion of new drugs covered [22] Biologics - Changchun High-tech's new drug, Vuxin Qibai monoclonal antibody, has been approved for treating acute gout arthritis, marking a significant advancement in biologics [29][34] - The drug shows rapid onset of action and a substantial reduction in recurrence risk, highlighting its clinical significance [33][34] Traditional Chinese Medicine - Lingrui Pharmaceutical's new indication for its nasal spray is expected to boost sales, with ongoing efforts to expand hospital coverage and OTC sales [38][41] Medical Devices - The report emphasizes policy support for high-end medical devices, predicting accelerated commercialization in various segments such as medical robots and AI [3][4] Medical Services - Recent policies to enhance maternity benefits are expected to stimulate demand in related services [3][4]

Group 1 - The core viewpoint of the articles highlights the performance and market position of Sanofi Biologicals, particularly in the blood glucose monitoring sector [1][2] - As of July 4, the stock price of Sanofi Biologicals closed at 22.28 yuan, with a PE ratio of 39.60 times and a total market capitalization of 12.572 billion yuan [1] - The average PE ratio in the medical device industry is 51.05 times, with a median of 36.62 times, placing Sanofi Biologicals at the 80th position in the industry ranking [1][2] Group 2 - In terms of capital flow, on July 4, Sanofi Biologicals experienced a net outflow of 1.6805 million yuan, with a total outflow of 14.5693 million yuan over the past five days [1] - The main business of Sanofi Biologicals includes the production and sales of blood glucose monitoring systems, along with related products such as diabetes nutrition and care products, blood lipid testing systems, and blood pressure monitors [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 1.042 billion yuan, a year-on-year increase of 2.76%, while net profit was 72.1151 million yuan, reflecting a year-on-year decrease of 10.90% [1]

Core Insights - The company, Sanofi Biologics, has announced that its self-developed "Continuous Glucose Monitoring System" has received EU Medical Devices Regulation (MDR) certification [1] - This system is designed to measure glucose levels in interstitial fluid for individuals aged 2 and above, aiming to replace traditional fingertip blood glucose tests for diabetes treatment decisions [1] - The second-generation CGM product features an integrated design that enhances user convenience and comfort while maintaining core technology [1] - The recent approval expands the applicable scenarios for both generations of the company's CGM products [1]

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-062 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于持续葡萄糖监测系统获得欧盟MDR认证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"或"三诺生物"）于近日收 到欧盟公告机构TÜV Rheinland德国莱茵的通知，公司自主研发的"持续葡萄糖 监测系统"新产品获得欧盟Medical Devices Regulation (EU) 2017/745（简称 "MDR"）认证。现将具体情况公告如下： 本次新增认证产品：Sinocare iCan Continuous Glucose Monitoring System (Model: i6, H6, i7, H7)；GlucoMen® iCan Continuous Glucose Monitoring System (Model: H6) 产品分类：IIb 证书编号：HZ 2068488-1 签批时间 ...